Desmopressin Acetate CAS 16789-98-3 Peptide Purity (HPLC) ≥98.5% Factory

Hazard Symbols Xn - Harmful
Risk Codes 20 - Harmful by inhalation
Safety Description 36 - Wear suitable protective clothing.
WGK Germany 3

Desmopressin Acetate (CAS: 16789-98-3) that is, 1-cysteine deamination and 8-D-arginine instead of 8-l-arginine, also known as arginine vasopressin, is a structural analog of natural arginine vasopressin, a derivative of vasopressin, its antidiuretic effect is more powerful and lasting than vasopressin, but no vasoconstrictor effect, drug side effects, clinical for congenital or drug-induced platelet dysfunction, uremia, liver cirrhosis and unknown causes caused by prolonged bleeding time; Can be used to control and prevent bleeding during small surgery; Central diabetes insipidus. In individual cases, this product will even produce efficacy in patients with moderate urinary system diseases, often disabled in patients with Type IIB von Willebrand disease.
Pharmacological action: Desmopressin Acetate contains desmopressin that is structurally similar to native arginine vasopressin. It is the difference between arginine vasopressin, mainly for the half of the amino acid and D arginine to replace L Arginine. These structural changes prolong the duration of action of the clinical dose of desmopressin without the side effects of compression. Some studies have shown that the effect of anti-enuresis is significant, which may be due to the increase of arginine vasopressin levels in the blood of children at night, and then concentrate the urine, reduce the urine volume and intravascular pressure, decreased neck and detrusor contraction.
Its efficacy, ease of administration (intranasal), long duration of action, and lack of side effects make itthe drug of choice for the treatment of central diabetesinsipidus. It may also be administered intramuscularly orintravenously. It is preferred to vasopressin injectionand oral antidiuretics for use in children. It is indicatedin the management of temporary polydipsia and polyuriaassociated with trauma to, or surgery in, the pituitary region.
Clinical Use: Desmopressin, as its acetate salt, is a synthetic analogue of vasopressin in which the Nterminal Cys is devoid of its α-amino function (1-Deamino) and where Arg8 is present as its D-isomer (D-Arg8), thus the commercial acronym DDAVP. The presence of D-Arg and the absence of the N-terminal amine in the desmopressin structure have increased its half-life such that it is available for oral, parenteral, or nasal use. It is used by all three of these routes of administration to prevent or control polydipsia (excessive thirst), polyuria, and dehydration of patients with diabetes insipidus caused by a deficiency of vasopressin. It also has been approved for the treatment of nocturnal enuresis (bed-wetting), which is believed to be caused by an absence of the normal night time rise in vasopressin levels. Desmopressin is known to cause an increase in both plasma factor VIII (antihemophilic factor) and plasminogen activator. It therefore is approved by the U.S. FDA for use, parenterally and nasally, in reducing spontaneous or trauma-induced bleeding episodes in patients with hemophilia A and type I Von Willebrand's disease, provided that their plasma factor VIII activity is greater than 5%. Stimate, the nasal spray used in treating patients with hemophilia A and type I Von Willebrand's disease, is 15-fold the concentration of DDAVP nasal spray; the latter is used in treating diabetes insipidus.